The role of IL-26 in innate and adaptive Immunity of Spondyloarthritis

Not Applicable

Recruiting

• Conditions: M07.39; M45.09

• Registration Number: DRKS00014672
• Lead Sponsor: Abteilung für Nephrologie, Klinikum rechts der Isar der TU München

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2018-05-03
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 170

Inclusion Criteria

Diagnosis of ankylosing spondylitis (modified New York criteria) or of psoriatric arthritis (CASPAR criteria) or of rheumatoid arthritis (EULAR/ACR criteria)
Age > 18 years
active disease
no biologics (anti-TNF, anti-CD20)
stable therapy regimen at recruitment

Exclusion Criteria

Failure of inclusion criteria
active infections or malignancy
other autoimmune disease
surgery less than 2 weeks prior to study inclusion
pregnancy
patient not capable of consent; no consent

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
evel of IL-26 in blood and synovial fluid of patients and controls measured by ELISA. Time point of measurement is identical with date of study inclusion. No longitudinal measurements.

Secondary Outcome Measures

Name	Time	Method
Identification of IL-26 producing cell types in blood and synovial fluid at time of study entry by flow cytometry.<br>Identification of IL-26 producing cells in synovial tissue at time of study entry by immunhistochemistry and -fluorescence.